KR100978705B1 - 폐암 치료 - Google Patents

폐암 치료 Download PDF

Info

Publication number
KR100978705B1
KR100978705B1 KR1020047014610A KR20047014610A KR100978705B1 KR 100978705 B1 KR100978705 B1 KR 100978705B1 KR 1020047014610 A KR1020047014610 A KR 1020047014610A KR 20047014610 A KR20047014610 A KR 20047014610A KR 100978705 B1 KR100978705 B1 KR 100978705B1
Authority
KR
South Korea
Prior art keywords
lung cancer
group
pharmaceutical composition
amrubicin
pharmaceutically acceptable
Prior art date
Application number
KR1020047014610A
Other languages
English (en)
Korean (ko)
Other versions
KR20040097178A (ko
Inventor
도시히로 노구찌
아께미 바바
Original Assignee
다이닛본 스미토모 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이닛본 스미토모 세이야꾸 가부시끼가이샤 filed Critical 다이닛본 스미토모 세이야꾸 가부시끼가이샤
Publication of KR20040097178A publication Critical patent/KR20040097178A/ko
Application granted granted Critical
Publication of KR100978705B1 publication Critical patent/KR100978705B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020047014610A 2002-03-18 2003-03-17 폐암 치료 KR100978705B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002074962 2002-03-18
JPJP-P-2002-00074962 2002-03-18
PCT/JP2003/003206 WO2003077932A1 (fr) 2002-03-18 2003-03-17 Medicaments contre le cancer des poumons

Publications (2)

Publication Number Publication Date
KR20040097178A KR20040097178A (ko) 2004-11-17
KR100978705B1 true KR100978705B1 (ko) 2010-08-30

Family

ID=28035342

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047014610A KR100978705B1 (ko) 2002-03-18 2003-03-17 폐암 치료

Country Status (10)

Country Link
US (1) US7091189B2 (zh)
EP (1) EP1488795B1 (zh)
JP (2) JP4786871B2 (zh)
KR (1) KR100978705B1 (zh)
CN (2) CN100400046C (zh)
AT (1) ATE545423T1 (zh)
AU (1) AU2003221036A1 (zh)
DK (1) DK1488795T3 (zh)
ES (1) ES2381408T3 (zh)
WO (1) WO2003077932A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46708E1 (en) 2002-03-06 2018-02-13 John C. Karamanos Embedded heat exchanger for heating, ventilation, and air conditioning (HVAC) systems and methods
US11841159B2 (en) 2002-03-06 2023-12-12 John Chris Karamanos Embedded heat exchanger with support mechanism
KR100978705B1 (ko) 2002-03-18 2010-08-30 다이닛본 스미토모 세이야꾸 가부시끼가이샤 폐암 치료
CN100438913C (zh) * 2004-11-22 2008-12-03 山东蓝金生物工程有限公司 一种抗癌药物组合物
CA2711802C (en) 2007-01-10 2016-08-16 John C. Karamanos Embedded heat exchanger for heating, ventilation, and air conditioning (hvac) systems and methods
US8822153B2 (en) * 2007-06-01 2014-09-02 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
US20110053879A1 (en) * 2008-02-08 2011-03-03 Poniard Pharmaceuticals, Inc. Picoplatin and amrubicin to treat lung cancer
CN109453195B (zh) * 2018-11-29 2021-04-20 湖南补天药业股份有限公司 一种用于抑制肿瘤细胞的药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077932A1 (fr) 2002-03-18 2003-09-25 Sumitomo Pharmaceuticals Co., Ltd. Medicaments contre le cancer des poumons

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US5330744A (en) * 1988-11-14 1994-07-19 Sloan-Kettering Institute For Cancer Research Method for increasing sensitivity to chemically induced terminal differentiation
US6747055B1 (en) * 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
TWI317285B (en) 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
CA2326004A1 (en) * 2000-11-02 2002-05-02 Richard E. Jones Methods for treating cellular proliferative disorders
EP1364652B1 (en) 2001-01-30 2014-04-09 Dainippon Sumitomo Pharma Co., Ltd. Remedies for lung cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077932A1 (fr) 2002-03-18 2003-09-25 Sumitomo Pharmaceuticals Co., Ltd. Medicaments contre le cancer des poumons

Also Published As

Publication number Publication date
AU2003221036A1 (en) 2003-09-29
DK1488795T3 (da) 2012-05-07
ATE545423T1 (de) 2012-03-15
KR20040097178A (ko) 2004-11-17
JP4786871B2 (ja) 2011-10-05
JPWO2003077932A1 (ja) 2005-07-14
US20050119196A1 (en) 2005-06-02
US7091189B2 (en) 2006-08-15
ES2381408T3 (es) 2012-05-28
CN101185652A (zh) 2008-05-28
CN100400046C (zh) 2008-07-09
EP1488795B1 (en) 2012-02-15
EP1488795A4 (en) 2007-07-25
WO2003077932A1 (fr) 2003-09-25
CN1652800A (zh) 2005-08-10
CN101185652B (zh) 2010-12-08
JP2011168621A (ja) 2011-09-01
EP1488795A1 (en) 2004-12-22

Similar Documents

Publication Publication Date Title
KR100695383B1 (ko) 암을 치료하기 위한 도세탁셀과 ｒｈｕＭＡｂ ＨＥＲ２의조합제제
US7449181B2 (en) Remedies for cancer
JP2011168621A (ja) 肺癌治療剤
WO2006029020A2 (en) Treatments of refractory cancers using na+/k+-atpase inhibitors
KR20080081249A (ko) 17-ａａｇ 또는 17-ａｇ, 또는 이 중 어느 하나의 전구약물과 ｈｅｒ２ 억제제의 조합을 사용하여 유방암을치료하는 방법
US20030212008A1 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
US20060183765A1 (en) Methods of treating cancer using an FPT inhibitor and antineoplastic agents
WO2023186075A1 (zh) 药物组合物、其用途及癌症的治疗方法
US20100092579A1 (en) Medicament for treating lung cancer
WO2005115391A1 (en) Method for treating abnormal cell growth
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
WO2024102650A1 (en) Intermittent dosing regimen for azenosertib in treating cancer
KR20050116166A (ko) 이리노테칸의 저항성 유방암 치료용 용도
CN114126656A (zh) 治疗癌症的方法和用途
Chen et al. Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours
EP2711009A1 (en) Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
AU2007201079A1 (en) Methods of treating cancer using an FPT inhibitor and antineoplastic agents

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130801

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20150717

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee